Revvity (NYSE:RVTY) Shares Up 5.2% – Should You Buy?

Revvity Inc. (NYSE:RVTY) shares rose 5.2% during mid-day trading on Thursday . The company traded as high as $148.53 and last traded at $149.4930. 1,039,798 shares traded hands during trading, a decline of 29% from the average daily volume of 1,467,490 shares. The stock had previously closed at $142.11.

Trending Headlines about Revvity

Here are the key news stories impacting Revvity this week:

• Positive Sentiment: New diabetes-testing solution: Revvity launched an IVDR-certified solution designed to help detect Type 1 diabetes at an early stage. The certification may improve the product’s commercial prospects in Europe and strengthen Revvity’s position in diagnostic testing. Revvity Launches IVDR-Certified Solution for Early Detection of Type 1 Diabetes
• Positive Sentiment: Recent operating momentum: Revvity’s latest reported quarter exceeded analyst expectations for both earnings and revenue, while its full-year 2026 EPS guidance remains $5.30-$5.40. The diabetes launch gives investors an additional potential growth catalyst as the company works to offset modest year-over-year revenue pressure. Top Midday Stories: Revvity’s New Diabetes Test
• Neutral Sentiment: Analyst stance remains cautious: Goldman Sachs maintained a Hold rating, consistent with the broader consensus Hold view. Several firms have assigned price targets below the stock’s recent trading range, suggesting investors may already be pricing in considerable improvement. Goldman Sachs Remains a Hold on Revvity
• Negative Sentiment: Insider selling: Insider Maxwell Krakowiak sold 1,631 shares for approximately $235,728, reducing his direct ownership by nearly 10%. The transaction is relatively small compared with Revvity’s market value, but it may add modest selling pressure or investor caution after the stock’s strong run. Revvity Insider Sells 1,631 Shares

Analysts Set New Price Targets

RVTY has been the topic of a number of recent analyst reports. Sanford C. Bernstein started coverage on shares of Revvity in a research note on Friday, June 26th. They issued a “market perform” rating and a $115.00 target price on the stock. Weiss Ratings raised shares of Revvity from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, July 30th. Wall Street Zen cut shares of Revvity from a “buy” rating to a “hold” rating in a research report on Sunday, August 16th. TD Cowen reaffirmed a “buy” rating on shares of Revvity in a report on Wednesday, July 15th. Finally, Royal Bank Of Canada initiated coverage on shares of Revvity in a research report on Tuesday, September 1st. They issued a “sector perform” rating and a $135.00 target price for the company. Four research analysts have rated the stock with a Buy rating and fourteen have issued a Hold rating to the company’s stock. According to MarketBeat.com, Revvity currently has an average rating of “Hold” and an average price target of $116.57.

Revvity Stock Up 6.5%

The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.50 and a current ratio of 1.80. The stock’s 50 day moving average price is $122.53 and its 200-day moving average price is $105.76. The company has a market cap of $16.88 billion, a PE ratio of 71.90, a PEG ratio of 2.61 and a beta of 1.09.

Revvity (NYSE:RVTY) last released its earnings results on Tuesday, August 4th. The company reported $1.41 earnings per share for the quarter, beating analysts’ consensus estimates of $1.21 by $0.20. Revvity had a return on equity of 8.34% and a net margin of 8.16%.The company had revenue of $729.69 million during the quarter, compared to analyst estimates of $702.96 million. During the same quarter in the previous year, the company posted $1.18 EPS. Revvity’s revenue for the quarter was down 1.3% on a year-over-year basis. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. On average, analysts predict that Revvity Inc. will post 5.36 earnings per share for the current year.

Revvity Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, November 13th. Investors of record on Friday, October 23rd will be paid a $0.07 dividend. This represents a $0.28 annualized dividend and a dividend yield of 0.2%. The ex-dividend date of this dividend is Friday, October 23rd. Revvity’s payout ratio is presently 13.33%.

Insiders Place Their Bets

In related news, insider Maxwell Krakowiak sold 1,631 shares of the company’s stock in a transaction on Monday, September 21st. The shares were sold at an average price of $144.53, for a total transaction of $235,728.43. Following the completion of the sale, the insider directly owned 14,781 shares in the company, valued at $2,136,297.93. This represents a 9.94% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Tajinder Vohra sold 7,330 shares of the firm’s stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $140.88, for a total transaction of $1,032,650.40. Following the completion of the sale, the insider directly owned 6,635 shares in the company, valued at approximately $934,738.80. This trade represents a 52.49% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 9,046 shares of company stock valued at $1,277,685 over the last quarter. 0.85% of the stock is currently owned by company insiders.

Institutional Trading of Revvity

Large investors have recently modified their holdings of the business. Ascentis Independent Advisors bought a new stake in shares of Revvity in the 1st quarter worth approximately $29,000. Global Retirement Partners LLC bought a new stake in shares of Revvity during the second quarter valued at approximately $51,000. SJS Investment Consulting Inc. boosted its stake in Revvity by 5,210.0% during the first quarter. SJS Investment Consulting Inc. now owns 531 shares of the company’s stock worth $47,000 after acquiring an additional 521 shares in the last quarter. Summit Securities Group LLC increased its stake in shares of Revvity by 294.6% during the first quarter. Summit Securities Group LLC now owns 663 shares of the company’s stock valued at $58,000 after purchasing an additional 495 shares in the last quarter. Finally, Contravisory Investment Management Inc. bought a new position in Revvity during the 1st quarter valued at approximately $66,000. 86.65% of the stock is owned by institutional investors.

About Revvity

Revvity, Inc is a life sciences and diagnostics company that provides technologies, products and services used by researchers, healthcare professionals and laboratories. Its offerings support applications across genomics, proteomics, cellular analysis, drug discovery, disease research and laboratory testing.

The company develops and supplies scientific instruments, reagents, consumables, software and workflow solutions. Its portfolio includes platforms for genetic and molecular analysis, imaging, high-throughput screening, biomarker research and single-cell analysis, as well as laboratory solutions used in areas such as reproductive health and newborn screening.

Revvity was established in 2023 following the separation of PerkinElmer’s Applied, Food and Enterprise Services businesses from its Precision Diagnostics operations.